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Available online 18 December 2015Previous studies have reported an increased prevalence of osteoporosis in Ehlers–Danlos syndrome (EDS), but
these were limited by a small number of patients and lack of information on fragility fractures. In this cross-
sectional study, we evaluated the prevalence of radiological vertebral fractures (by quantitative morphometry)
and bone mineral density (BMD, at lumbar spine, total hip and femoral neck by dual-energy X-ray absorptiom-
etry) in 52 consecutive patients with EDS (10males, 42 females;median age 41 years, range: 21–71; 12with EDS
classic type, 37 with EDS hypermobility type, 1 with classic vascular-like EDS, and 2 without speciﬁc classiﬁca-
tion) and 197 control subjects (163 females and 34males; median age 49 years, range: 26–83) attending an out-
patient bone clinic. EDS patients were also evaluated for back pain by numeric pain rating scale (NRS-
11).Vertebral fractures were signiﬁcantly more prevalent in EDS as compared to the control subjects (38.5% vs.
5.1%; p b 0.001) without signiﬁcant differences in BMD at either skeletal sites. In EDS patients, the prevalence
of vertebral fractures was not signiﬁcantly (p= 0.72) different between classic and hypermobility types. BMD
was not signiﬁcantly different between fractured and non-fractured EDS patients either at lumbar spine (p =
0.14), total hip (p=0.08), or femoral neck (p=0.21). Severe back pain (≥7 NRS) wasmore frequent in EDS pa-
tients with vertebral fractures as compared to thosewithout fractures (60% vs. 28%; p=0.04). In conclusion, this
is the ﬁrst study showing high prevalence of vertebral fractures in a relatively large population of EDS patients.
Vertebral fractures were associated with more severe back pain suggesting a potential involvement of skeletal
fragility in determining poor quality of life. The lack of correlation between vertebral fractures and BMD is con-
sistent with the hypothesis that bone quality may be impaired in EDS.






Ehlers–Danlos syndromes (EDS) are a heterogeneous group of con-
nective tissue disorders clinically characterized by skin hyperestensibility,
articular hypermobility, and tissue fragility affecting skin, ligaments,
joints, blood vessels, and internal organs [1]. Six types of EDS are reported
in the Villefranche nosology: the classic type with prevalent cutaneous
and articular involvement is due to mutations in COL5A1 or COL5A2
genes encoding type V collagen; the hypermobility type, also known as
joint hypermobility syndrome, with prominent musculoskeletal features
is without known molecular defects; the vascular type with vascular
and internal organs fragility is caused by COL3A1 mutations leading to
type III collagen defects; the kyphoscoliotic type with early onset, 25123 Brescia, Italy.progressive kyphoscoliosis is due to mutations in PLOD1 encoding lysyl
hydroxylase 1; the arthrochalasis typewith congenital bilateral hip dislo-
cation is related to a speciﬁc set of mutations in COL1A1 or COL1A2 genes
coding for type I collagen; and dermatosparaxis with pronounced skin
fragility and redundance is caused by mutations in ADAMTS2 encoding
procollagen I N-proteinase [2]. The most frequent EDS are the classic
and hypermobility types, whereas the others are rare with variable clini-
cal overlap [3]. Among these, the classic vascular-like type is an extremely
rare EDS form characterized by cutaneous, articular and vascular involve-
ment [4]. A subset of patients with overlapping phenotypes not ﬁtting
into the EDS types described so far are deﬁned as not classiﬁed EDS [1].
Collagen types I, III and V, which are distributed in several
connective tissues, i.e., skin, ligaments, tendons, blood vessels, and in-
ternal viscera are abnormal in EDS [5]. Type V collagen plays a central
role in collagen ﬁbrillogenesis and co-assembles with type I collagen
to form heterotypic ﬁbrils [6]. Abnormalities of type I and V collagen
ﬁbers may cause skeletal fragility by irregular arrangement of hydroxy-
apatite crystals and non mineralized collagen ﬁbrils [7]. As a matter of
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form normally mineralized bone [8,9].
Preliminary studies reported that patients with EDS may have low
bone mineral density (BMD) [10–15], whereas data on fragility
fractures are limited to a few reports based on a retrospective historical
assessment of the prevalence of clinical fractures [12,15]. Current
knowledge supports the clinical relevance of radiologically diagnosed
vertebral fractures [16], but they have been investigated in only a few
EDS patients [11], being therefore still unclear the association of EDS
with an increased risk of vertebral fractures.
In this cross-sectional study, we aimed at evaluating the prevalence
of radiological vertebral fractures in a relatively large population of
adult patientswith different EDS types.Moreover, we aimed at studying
whether radiological vertebral fractures were related to BMD and
inﬂuenced the severity of back pain in patients with EDS.
2. Materials and methods
2.1. Subjects
Fifty-two consecutive patients with EDS (10 males, 42 females;
median age 41 years, range: 21–71) were enrolled in the study.
Inclusion criteria: 1) age older than 18 years; and 2) diagnosis of EDS.
The clinical diagnosis of EDS classic and hypermobility type was
based on Villefranche nosology [2]. Joint hypermobility syndrome, also
known as EDS hypermobility type, was diagnosed using the Brighton
criteria [17]. Sixteen patients were on treatment with drugs potentially
affecting bone metabolism [18]. Speciﬁcally, 13 patients were treated
with proton pump inhibitors, two patients with selective inhibitors of
serotonin reuptake and one patient with anticonvulsivant drug
(lamotrigine).
Exclusion criteria were: 1) treatment with anti-osteoporotic drugs,
except for calcium and vitamin D; 2) prolonged immobilization;
3) spine trauma; and 4) previous surgical intervention on the spine
except for correction of scoliosis in infancy [19].
The study was approved by the local ethical committee and the pa-
tients gave informed consent to the study and authorized theprocessing
of their personal data according to Italian bioethics laws.
One hundred ninety-seven subjects (163 females and 34 males;
median age 49 years, range: 26–83) without family history and clinical
evidence of EDS were enrolled as control group. The control subjects
were retrospectively selected from a population of patients consecu-
tively attending our bone outpatient units in the same period as that
of EDS patients enrollment. The criteria used to select control subjects
were: 1) comparable age to EDS patients; 2) comparable sex to EDS
patients; and 3) availability of dual-energy X-ray absorptiometry
(DXA) scans and spine X-rays. DXA scans were performed because of
anamnestic/clinical risk factors for osteoporosis. Spine X-rays were per-
formed for the following reasons: DXAdiagnosis of osteoporosis or BMD
“below the expected range for age” or osteopenia with risk factors for
fragility fractures, back pain and/or historical height loss. Exclusion
criteria were: 1) previous or actual treatment with anti-osteoporotic
drugs, except for calcium and vitamin D; 2) treatment with drugs
known to cause osteoporosis [18]; and 3) history of chronic diseases
causing secondary osteoporosis.
2.2. Methods
BMD of the lumbar spine, total hip and femoral neck was measured
by DXA (Hologic Inc., Waltham, MA). Fractured vertebrae were
excluded from the lumbar BMD analysis. DXA results were expressed
in BMD (g/cm2). In aged 50 years or older subjects (21 patients with
EDS and 79 control subjects), BMD was also expressed as T-score,
comparing the results with those obtained in a sex-matched Caucasian
population at peak of bone mass [20]. A T-score less than or equal to
−2.5 SD at the hip or spine was deﬁned as osteoporosis, whereasosteopeniawas deﬁned as a T-score between−1 and−2.5 SD. In youn-
ger than 50 years subjects (31 patients with EDS and 118 control sub-
jects), the results were expressed as Z-score, comparing the results
with those obtained in an age and sex-matched Caucasian population
[20]. A Z-score less than or equal to −2.0 SD was used to deﬁne a
BMD “below the expected range for age” [20].
Vertebral fractures were assessed by a quantitative morphometric
approach [21]. Using a translucent digitizer and a cursor, six points
were marked on each vertebral body to describe vertebral shape. Ante-
rior (Ha), middle (Hm), and posterior (Hp) vertebral heights weremea-
sured and height ratios (Ha/Hp, Hm/Hp, Hp/Hp of the above vertebrae,
and Hp/Hp of the below vertebrae) were calculated for each vertebra
from T4 to L4; the fractures were deﬁned mild, moderate and severe
based on a height ratio decrease of 20–25%, 26–40% and more than
40%, respectively [21]. The morphometric analysis was performed by a
single operator (M.D.). The intra-observer coefﬁcient of variation, eval-
uated on a series of 10 measurements, was between 4% and 8%.
Pain was assessed using the numeric, 10-point, rating scale (NRS-
11) in all patients; conventionally, severe pain was considered by a
score over 7 [22].
For the molecular characterization of EDS patients, genomic DNA
was extracted from peripheral blood leukocytes using standard proce-
dures. Classic EDS patients carried either a COL5A1 or a COL5A2 muta-
tion; the classic vascular-like EDS patient carried the COL1A1
c.934C N T (p.Arg312Cys) mutation [4]. The EDS hypermobility type
and the not classiﬁed EDS patients were not molecularly characterized.
All of the exons and intron-ﬂanking regions of the COL5A1, COL5A2 and
COL1A1 genes were PCR ampliﬁed by using optimized genomic primer
sets as previously described [4]. PCR products were bidirectionally se-
quenced using the BigDye Terminator Cycle Sequencing kit (Applied
Biosystems, Carlsbad, CA) and separated on an ABI 3130XL Genetic An-
alyzer (Applied Biosystems) [4].
Vitamin D status of EDS patients was retrospectively assessed using
serum 25-hydroxyvitamin D values measured within 1 month before
the enrollment and available in the clinical ﬁles. Hypovitaminosis D
was deﬁned by serum 25-hydroxyvitamin D values below 30 ng/ml.
2.3. Statistical analysis
All data were expressed as the median and range. Un-paired data
were compared usingMann–Whitney test. Frequencies were compared
using chi-square test with Fisher correction, when appropriate. A logis-
tic regressionmodelwas used in the statistical analysis of risk factors for
the occurrence of vertebral fractures. Statistical signiﬁcance was as-
sumed when p-values were equal or less than 0.05.
3. Results
EDS patients and control subjects showed no signiﬁcant differences
in BMD at lumbar spine (0.99 g/cm2, range: 0.64–1.40 vs. 1.01 g/cm2,
range: 0.50–1.35; p = 0.70), total hip (0.85 g/cm2, range: 0.54–1.30
vs. 0.88 g/cm2, range: 0.72–1.30; p = 0.09) and femoral neck
(0.79 g/cm2, range: 0.55–1.10 vs. 0.90 g/cm2, range: 0.51–1.00; p =
0.20). In 50 years or older EDS patients (21 cases), osteopenia and oste-
oporosis were found in seven (33.3%) and one (4.8%) patient, respec-
tively, without statistically signiﬁcant difference with respect to
control subjects (43% osteopenia; 19% osteoporosis; p= 0.10 vs. EDS).
In younger EDS patients (31 cases) and control subjects (118 cases),
the prevalence of BMD “below the expected range for age” at either
skeletal site was 32.3% and 24.6%, respectively (p= 0.49).
Patientswith hypermobility EDS showed signiﬁcantly lower femoral
neck BMD (0.75 g/cm2, range: 0.55–1.07) as compared to classic EDS
(0.88 g/cm2, range: 0.71–1.15; p = 0.01 vs. hypermobility EDS) and
control subjects (0.90 g/cm2, range: 0.51–1.00; p= 0.03 vs. hypermo-
bility EDS), without signiﬁcant differences in lumbar spine and total
hip BMDs (data not shown).
Fig. 1. Prevalence, number and severity of vertebral fractures (VFs) in patients with
Ehlers–Danlos syndrome (EDS) as compared to control subjects. a, p b 0.05 EDS patients
vs. control subjects.
Fig. 2. Prevalence of vertebral fractures (VFs) in relationship with bone mineral density
(BMD) in patients with Ehlers–Danlos syndrome (EDS) and control subjects with age
b50 (3a) or ≥50 (3b) years. a, p b 0.05 EDS patients vs. control subjects; b, p b 0.05 patho-
logical BMD vs. normal BMD.
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pared to control subjects (Fig. 1),without signiﬁcant difference between
classic and hypermobility EDS (45.5% vs. 39.5%; p = 0.72). Eleven pa-
tients had a single fracture, whereas in 9 patients two or more vertebral
fractures were found. The fractures were mild in 14 patients, while the
remaining 6 patients had moderate or severe fractures. In EDS patients,
higher number per patient and more severe vertebral fractures as com-
pared to control subjects were found (Fig. 1). Patients with vertebral
fractures showed no signiﬁcant differences in age, sex, type of EDS,
BMD and serum 25-hydroxyvitamin D values as compared to patients
who did not fracture (Table 1).
Stratifying the subjects for age, the prevalence of vertebral fractures
was signiﬁcantly higher in EDS patients as compared to control subjects
either before (Fig. 2a) or after 50 years of age (Fig. 2b). Stratifying the
subjects also for BMD, vertebral fractures were more prevalent in EDS
patients with pathological BMD (i.e., osteopenia, osteoporosis or BMD
below “the expected range for age”) with respect to patients with nor-
mal BMD (Fig. 2a,b). However, EDS patients with normal BMD main-
tained higher prevalence of vertebral fractures as compared to control
subjects either before (Fig. 2a) or after 50 years of age (Fig. 2b). In detail,
amongpatients younger than 50 years (31 cases), vertebral fractures oc-
curred in 13 patients (41.9%) and only 6 of them showed BMD Z-score
below−2 SD at either site. Among older patients with vertebral frac-
tures (7 cases), three had normal BMD, whereas osteopenia and osteo-
porosis were found in three and one patient, respectively.
Thirty-nine EDS patients (75%) complained of back pain. In these pa-
tients, severe back pain (≥7 according to NRS-11 scale)was signiﬁcantly
associated with prevalence (odds ratio: 3.88, C.I.95% 1.17–12.48; p =
0.02) and more severe (odds ratio: 2.51, C.I.95% 1.01–5.83; p = 0.03)
vertebral fractures. In fact, prevalence and severity of vertebral fracturesTable 1
Demographical and clinical features in Ehlers–Danlos syndrome (EDS) patients with vertebral f
as median and ranges and the comparisons were performed using non-parametric tests.
Features EDS patients without VFs
Cases 32
Age (years) 40 (from 21 to 71)
Sex (males/females) 7/25
EDS type (Classic/hypermobility) 6/23
Lumbar BMD (g/cm2) 1.05 (from 0.64 to 1.40)
Lumbar BMD T-score (SD) −0.6 (from−3.5 to +2.1)
Total hip BMD (g/cm2) 0.98 (from 0.69 to 1.30)
Total hip BMD T-score (SD) −0.2 (from−2.5 to +1.7)
Femoral neck BMD (g/cm2) 0.82 (from 0.59 to 1.10)
Femoral neck BMD T-score (SD) −0.8 (from−3.5 to +1.6)
Serum 25-hydroxyvitamin D (ng/ml) 23 (from 5 to 70)were signiﬁcantly higher in patients with severe back pain as compared
to those with either moderate or absent back pain (Fig. 3).
Hypovitaminosis D was found in 42 patients (80.8%). At enrollment,
15 EDS patients with hypovitaminosis D were on treatment with vita-
min D3, with (4 cases) or without (11 cases) calcium carbonate.
Hypovitaminosis D was not correlated with vertebral fractures (odds
ratio: 0.92, C.I.95% 0.22–3.78; p = 0.91), BMD (odds ratio: 0.73,
C.I.95% 0.16–3.35; p = 0.19) and back pain (odds ratio: 1.1, C.I.95%
0.38–2.19; p= 0.83).ractures (VFs) as compared to those who did not fracture. Continuous datawere presented
EDS patients with VFs p-values
20
42 (from 24 to 59) 0.55
3/17 0.54
5/15 0.72
0.87 (from 0.78 to 1.23) 0.14
−1.0 (from−3.4 to +1.2) 0.17
0.83 (from 0.54 to 1.03) 0.08
−1.1 (from−3.2 to +0.3) 0.07
0.75 (from 0.55 to 0.96) 0.21
−1.1 (from−2.7 to +0.2) 0.13
20 (from 7 to 87) 0.29
Fig. 3. Prevalence and severity of vertebral fractures (VFs) in patients with severe back
pain as compared to mild/moderate or absent back pain. a, p b 0.05 severe vs. mild and
moderate back pain.
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This cross-sectional study reported for the ﬁrst time high prevalence
of radiological vertebral fractures in adults with EDS, even in the pres-
ence of normal BMD as assessed by DXA. The presence and severity of
vertebral fractures were signiﬁcantly associated with back pain in this
clinical setting.
EDS refers to a group of heritable connective tissue disorders caused
by alterations in different collagen genes and in genes encoding en-
zymes involved in maturation of ﬁbrillary collagens leading to abnor-
malities in extracellular matrix in several systems and organs [1,2].
Approximately 90% of bone matrix is composed of collagen which
serves as a tissue scaffold but also provides a substrate for cell anchorage
and regulates bioavailability of growth factors and cytokines [23]. Ade-
quate quality collagen is required to form normally mineralized bone.
Moreover, collagenmay regulate the function of bone cells and in exper-
imental animals the lack of collagenwas associatedwith an impairment
of osteoblastogenesis [24]. The mechanism leading to skeletal fragility
in EDS may be similar to those occurring in osteogenesis imperfecta, a
disease due to a primitive defect in type I collagen synthesis [7]. In
EDS, type I collagen is not frequently mutated but the defects of other
types of collagen (e.g., type V collagen) may also lead to misalignment
of type I collagen molecules and abnormal ﬁbrillogenesis [6], with ab-
normal structure of extracellular bonematrix and possible secondary al-
terations in bone remodeling [25]. Another mechanism potentially
involved in the skeletal fragility of EDS is hypomobility due to joint
and muscle involvement. In fact, bone loss at proximal femur was
shown to be closely correlated with levels of physical activity in EDS
[13].
Over the last 20 years several studies have reported a variable degree
of bone loss in patients with EDS [10–15]. Differently from previous
studies, we provided an age-related densitometric deﬁnition of low
BMD, since the majority of patients with the disease are relatively
young. Interestingly, we observed that more than 50% of our patients
had normal BMD. Indeed, osteoporosis was found in only one patient
older than 50 years, whereas BMD “below the expected range for age”
was observed in slightly more than one third of younger patients with
EDS. These percentages were lower than those previously reported in
smaller series [10,11] and in studies using different densitometric
criteria [15]. Notwithstanding the relatively reassuring densitometric
data, we observed high prevalence of vertebral fractures in patients
with EDS. Vertebral fractures are the hallmark of osteoporosis and the
radiological approach has emerged as the method of choice for evaluat-
ing their true prevalence in population studies [21]. Using this approach,
our study reported for the ﬁrst time vertebral fractures in more than30% of patients with EDS, a similar percentage to that already reported
in other conditions at very high risk of fragility fractures [26–30]. It is
noteworthy that fracture risk in this study was not associated with pa-
tient age, with prevalence of vertebral fractures being high in both
young and older patients. This ﬁnding is in agreement with previous
studies reporting high prevalence of vertebral fractures in young adults
with skeletal fragility [28–30] and consistent with the hypothesis that
deterioration in bone quality and strength during the ﬁrst decades of
life may lead to early development of fractures in patients with second-
ary osteoporosis. Interestingly, prevalence of vertebral fractureswas not
different between classic and hypermobility EDS, suggesting that
degree of bone damage may be similar notwithstanding the different
genetic background, but in agreement with the similar and partly over-
lapping clinical presentation of these disorders. It is noticeable that in
these two EDS types collagen and elastin alterations in skin biopsies
are identical; in particular, irregular and fragmented collagen ﬁbrils,
and cauliﬂower ﬁbrils as a hallmark of disturbed ﬁbrillogenesis of the
heterotypic type I/V collagen ﬁbrils are described [31].
In our study, vertebral fractures were found even in patients with
normal or low-normal BMD, such as already observed in other forms
of secondary osteoporosis [32,33]. Indeed, BMD reﬂects bone quantity
but not bone quality which is determined by structural and material
properties [9]. Our study suggests that in EDS abnormal collagen syn-
thesis may lead prevalently to impairment of bone quality. As a matter
of fact, this hypothesis is consistent with previous observations that
ultrasonometric bone parameters were shown to be compromised
more than BMD in EDS patients [12].
We reported for the ﬁrst time high prevalence of hypovitaminosis D
in EDS patients. Indeed, malabsorption caused by collagen abnormali-
ties may be a potential cause of hypovitaminosis D in patients with
EDS [34]. In the general population, vertebral fractures were associated
with hypovitaminosis D [35], especially when accompanied by second-
ary hyperparathyroidism [36]. Such an association was not observed in
this study, possibly due to limited number of EDS patients with normal
vitamin D values, lack of information on serum parathyroid hormone
values associated with hypovitaminosis D, cross-sectional design of
the study which did not allow to investigate the temporal relationship
between untreated hypovitaminosis D and development of vertebral
fractures. Moreover, the retrospective evaluation of vitamin D status
did not allow to exclude possible inter-assay variability in 25-
hydroxyvitamin D measurement.
Some limitations of our studymeritmention. The cross-sectional de-
sign of this analysis did not allow to investigate the timing of develop-
ment of vertebral fractures in EDS. Moreover, our control population
demonstrated to be at relatively low risk of osteoporosis and fractures
[37]. Therefore, large differences observed between our patients and
controls may not reﬂect an incremental risk of fractures in EDS with re-
spect to other high risk conditions [26–30,32,37], although the preva-
lence of vertebral fractures in our EDS patients was higher than that
already reported in the general population [38,39]. Moreover, we did
not measure biochemical markers of bone turnover [40] and we did
not evaluate bone microstructure in relationship with prevalent verte-
bral fractures [12,21].
Besides the aforementioned limitations, the results of our studymay
be clinically relevant, since they suggest that skeletal fragility may be a
frequent complication of EDS. The occurrence of vertebral fractures
even in the presence of normal BMD suggests that DXA measurement
may not well reﬂect the bone health status and that vertebral fracture
assessment should be included in the diagnostic work-up of EDS, espe-
cially in patients with back pain whichwas shown to negatively impact
on quality of life [41–43].
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